Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06941181 · ClinicalTrials.gov registry record · NA
Neurocognitive Predictors of Health Risk Behaviors
A NA study of Substance Use, sponsored by Virginia Polytechnic Institute and State University.
- Active
- Registry status
- NA
- Development phase
- 117
- Enrollment target
- 2
- Study locations
NCT06941181: Active NA study of Substance Use, sponsored by Virginia Polytechnic Institute and State University.
NCT06941181 is a NA study of Substance Use that is active but no longer recruiting, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 117 participants, below the 1,259-participant average among 88 other Substance Use trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06941181, a NA study of Substance Use, is active but no longer recruiting, sponsored by Virginia Polytechnic Institute and State University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 117 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study proposes to extend the ongoing longitudinal study of health risk behaviors and obtain new data from former adolescents (followed previously from ages 13-22; Times 1-8) now from ages 23 to 28 (Times 9-11). The goal of this study is to examine the contribution of developing neurocognitive markers to substance use in young adulthood by following a well-characterized longitudinal sample.
Primary Outcome
Frequency (past year and past month use) of cigarette/tobacco, alcohol, cannabis, and other drug use will be asked.
Conditions Studied
Interventions
- OTHER neurocognitive tasks
Study Locations (2)
Virginia
- Virginia Tech - Blacksburg
- Fralin Biomedical Research Institute at VTC - Roanoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2014-01-20 |
| Est. Completion | 2029-05-31 |
| Phase | NA |
What the registry record for NCT06941181 still lists
NCT06941181 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 1,259-participant average among 88 other Substance Use trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Substance Use appearing as the primary indexed condition, and to 1 intervention - of which neurocognitive tasks is the first listed.
NCT06941181 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06941181 about?
NCT06941181 is a clinical study titled "Neurocognitive Predictors of Health Risk Behaviors". This study proposes to extend the ongoing longitudinal study of health risk behaviors and obtain new data from former adolescents (followed previously from ages 13-22; Times 1-8) now from ages 23 to 28 (Times 9-11). The goal of this study is to examine the contribution of developing neurocognitive m...
What is the current status of trial NCT06941181?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 117 participants. The study started on 2014-01-20. Estimated completion is 2029-05-31.
What conditions does trial NCT06941181 study?
This clinical trial studies the following conditions: Substance Use.
What interventions are being tested in trial NCT06941181?
The interventions under investigation include: neurocognitive tasks (OTHER).
Who is sponsoring clinical trial NCT06941181?
This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06941181 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06941181's enrollment target sits among peer trials
117 60th of 88 higher than 29 of 88 other Substance Use trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Native Spirit: Significant Aim 3: Intervention
RECRUITING · NA
-
Parent SMART (Substance Misuse in Adolescents in Residential Treatment)
RECRUITING · NA
-
Cultural Adaptation of Drug Treatment for DJJ Youth
RECRUITING · NA
-
Adaptation and Evaluation of Bright Horizons
RECRUITING · NA
-
Teen Health Choices & Wellness
RECRUITING · NA
-
Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women with Trauma-related Conditions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03539822 · 117 participants · Phase 1
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
- NCT03786692 · 117 participants · Phase 2
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
- NCT04479696 · 117 participants · NA
Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- NCT04940585 · 117 participants · NA
ROSE in Sunset Park
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI